A Phase II Clinical Study of Efficacy and Safety of HRS-1780 Tablets and Henagliflozin Proline Tablets in the Treatment of Patients With Chronic Kidney Disease (Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Design).

This document provides information about a clinical trial for a drug called HRS-1780 tablet, which is being compared to a placebo and another drug called Henagliflozin Proline. The trial is not yet recruiting participants and aims to enroll 180 men and women between the ages of 18 and 75. The estimated completion date for the trial is April 2025. The eligibility criteria for participants are outlined, and the trial is being conducted by Shandong Suncadia Medicine Co., Ltd. The document also includes administrative information such as the NCT number and responsible party. [Extracted from the article]